To characterize the blood component mediating the therapeutic efficacy of ABT for AD , we evaluated the clinical efficacy of autologous plasma therapy ( APT ) and autologous high-molecular-weight plasma protein fraction therapy ( AHPT ) in patients with AD in this study .